In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgevita Launch In Finland Is No Counterbalance For Remsima Loss, Orion Anticipates

Executive Summary

Intensified competition and declining prices, coupled with a failure to scoop winner-takes-all tenders in certain Nordic markets, took a huge bite out of Orion’s biosimilars sales in 2018. Launching the first Humira biosimilar in Finland will not plug the gap, the company has stated.

You may also be interested in...

European hopes were too high, says Orion

There is “no question that the overall biosimilar industry was too optimistic on the pricing of biosimilars, at least in the European context”, according to Orion’s president and chief executive officer, Timo Lappalainen.

Amgen enlists Orion for Finnish Amgevita

Amgen and Orion have struck a sales and marketing collaboration for the US firm’sAmgevita (adalimumab) biosimilar in Finland. The deal for “Finland’s first adalimumab biosimilar” comes as Amgen competes with Biogen, Mylan and Sandoz to take market share in Europe away from AbbVie’s Humira reference brand after the arthritis blockbuster lost its supplementary protection certificate (SPC) monopoly in mid- October (Generics bulletin, 26 October 2018, page 1).

Orion sets sights on Seretide and Spiriva

Orion has during October started to ship in Europe its Flusarion Easyhaler alternative to GlaxoSmithKline’s Seretide (salmeterol/ fluticasone) asthma therapy. And the Finnish firm is also conducting bioequivalence studies with a view to using its Easyhaler dry-powder inhaler (DPI) device to offer a rival to Boehringer Ingelheim’s Spiriva (tiotropium) chronic obstructive pulmonary disease (COPD) blockbuster.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts